The National Heart, Lung, and Blood Institute recommends the following levels:. Anything less than that increases your risk of heart disease. The following conditions can affect the liver in a way that causes cholesterol levels to be abnormal. The most common form of liver malfunction is nonalcoholic fatty liver disease NAFLD.

It affects approximately one-quarter of the population. NAFLD is associated with dyslipidemia , abnormal levels of cholesterol and similar compounds in the blood. NAFLD also can trigger lipodystrophy , irregularities in how the body distributes fat. NAFLD covers a spectrum of conditions.

Within NAFLD is the more serious non-alcoholic steatohepatitis NASH. A diagnosis of NASH often leads to cirrhosis, liver failure, and hepatocellular carcinoma. Cirrhosis can cause scarring and prevent the liver from carrying out basic metabolic functions. The condition is a reaction to long-term injury to the organ.

The injury can include inflammation from a disease such a hepatitis C. After hepatitis C, long-term alcohol abuse is the most common cause of cirrhosis in the United States. Another significant cause of liver problems is damage from drugs. That makes it susceptible to injury from prescription, over-the-counter, or recreational drugs.

Acute hepatitis. Chronic hepatitis. After discontinuing the drug, liver damage is typically not severe and often subsides.

In rare cases, the damage can be severe or permanent. Read more: Fatty liver ». High levels of LDL cholesterol increase the risk of fatty deposits on vessels that bring blood to the heart.

Too-low levels of HDL cholesterol suggest the body may not be able to clear plaques and other fatty deposits from the body. Both conditions create a risk for heart disease and heart attack. Liver damage can progress for months or years with no symptoms. By the time symptoms appear, liver damage often is extensive.

Some symptoms warrant a visit to the doctor. These include:. A doctor may be able to diagnose liver problems by observing your symptoms and completing a medical history.

You may also undergo tests of your liver function. These tests include. Liver enzyme test : Common enzymes in this panel are alanine transaminase, aspartate transaminase, alkaline phosphatase, and gamma-glutamyl transpeptidase. High levels of any of these enzymes may indicate damage.

Liver protein test : Low levels of the proteins globulin and albumin can show a loss of liver function. Prothrombin is a liver protein needed for clotting.

A common test measures how long it takes for your blood to clot. Slow clotting time can mean a lack of prothrombin and liver damage. Bilirubin test : The blood transports bilirubin to the liver and gallbladder.

Blood in the urine or excess bilirubin in the blood can show liver damage. Single lipoprotein panel : The panel tests blood cholesterol and tryglycerides together. Blood typically is drawn after fasting.

Read more: Liver function tests ». Treatment of liver disorders often starts with addressing the underlying condition. Different liver conditions call for specific dietary changes, but the American Liver Foundation has some general tips.

Treatment of high cholesterol includes dietary guidelines like those for liver disease. Medical treatment of high cholesterol also often includes a class of drugs called statins. Researchers have looked at whether statins are safe for people with liver disease to use.

Therapeutic interventions promise more effective control of cholesterol, even among people with liver disease. But lifestyle changes and dietary control remain important and effective parts of a complete approach to cholesterol control with liver involvement.

The National Heart, Lung, and Blood Institute suggests how to control high levels of blood cholesterol with diet and lifestyle changes:. Bernstein suggests these lifestyle guidelines are good advice for anyone trying to keep cholesterol in check, including those with the added challenge of underlying liver disease.

Our experts continually monitor the health and wellness space, and we update our articles when new information becomes available. Learn what you need to know about…. There are two kinds of cholesterol — HDL and LDL. Learn why LDL is usually considered "bad" and what to do if you have too much.

Angelica Pierce was diagnosed with high cholesterol at 15 and tried for years to unsuccessfully manage it with diet and exercise alone. Then, a…. A doctor may recommend a cholesterol test if a person has a family history of heart disease , a medical condition such as diabetes, or if they are overweight.

A liver biopsy or liver function test is usually used to diagnose liver disease. A biopsy will remove a tiny piece of liver tissue to test for disease.

A liver function test is a blood test that can measure proteins and enzymes in the blood. A person can make lifestyle changes and sometimes take medication to treat high cholesterol.

Usually, they will be encouraged to make changes to diet and exercise first. If they are overweight, they may be advised to lose weight. The most common medication is statins, which a person needs to take for life. Statins are drugs that block a chemical in the liver that makes cholesterol.

Treatment for liver disease depends on what type of liver disease a person is experiencing. It will usually involve lifestyle changes, medication, or sometimes, a liver transplant if the liver is too damaged to function. Diet can help to cut the risk of developing liver disease and may reduce its impact.

Keeping to a healthy weight is an essential way to maintain good overall health. What a person is recommended to eat or drink may be different for each specific liver disease. A doctor will be able to advise on diet and exercise.

A person who has alcohol-related liver disease will usually be advised to stop drinking alcohol. Eating enough protein and carbohydrates as part of a balanced diet can help maintain a healthy weight.

Cutting down on fatty foods may reduce the impact of a fatty liver or NAFLD. Eating plenty of fruits and vegetables, and foods such as bread and potatoes that release energy slowly can help.

A diet with plenty of protein is a way of obtaining adequate energy supplies without eating high-cholesterol foods. Eggs, nuts, chicken breast, and pulses are excellent sources of protein.

Eating regularly and snacking between meals can be a healthful way for a person to get enough fuel. A person can help prevent health problems, such as damage to the liver, by reducing high levels of LDL cholesterol. Saturated fats contain a high level of cholesterol.

Many fast foods, cakes, butter, fatty meats such as sausages, full-fat cheese, and cream contain saturated fats. Giving up smoking can also be beneficial. Making changes to diet and exercise are ways a person can manage high cholesterol.

And they will need to maintain these changes to avoid high cholesterol returning. The liver can repair itself up to a certain point. This means that someone may be able to reduce the damage that has been done if they discover liver disease at an early stage.

Losing weight if needed, eating a healthful diet, exercising, and cutting down on alcohol can help to reduce the impact of liver disease. High cholesterol does not usually cause obvious symptoms. In this article, we will look at the effects of cholesterol on the body and how to lower the….

Most types of cheese are high in cholesterol and saturated fat. Studies provide conflicting information about the relationship between cheese and…. In this article, learn about the different kinds of cholesterol, what different factors affect cholesterol levels, and when to contact a doctor.

My podcast changed me Can 'biological race' explain disparities in health? Why Parkinson's research is zooming in on the gut Tools General Health Drugs A-Z Health Hubs Health Tools Find a Doctor BMI Calculators and Charts Blood Pressure Chart: Ranges and Guide Breast Cancer: Self-Examination Guide Sleep Calculator Quizzes RA Myths vs Facts Type 2 Diabetes: Managing Blood Sugar Ankylosing Spondylitis Pain: Fact or Fiction Connect About Medical News Today Who We Are Our Editorial Process Content Integrity Conscious Language Newsletters Sign Up Follow Us.

Medical News Today. Health Conditions Health Products Discover Tools Connect. How are liver function and cholesterol production linked? Medically reviewed by Saurabh Sethi, M. Healthy levels Effects Diagnosis Treatment Diet Prevention Takeaway Most cholesterol in the body is made in the liver and is necessary for good health.

A total amount of ~1,—1, mg of cholesterol is presented in the intestine on a daily basis for absorption Cholesterol uptake by enterocytes is mainly mediated by the specific transporter protein Niemann-Pick C1 Like 1 NPC1L1 , which is abundantly expressed on the brush-border membrane of small-intestinal enterocytes 8 , 11 Figure 1.

Cholesterol is esterified by acetyl-CoA cholesterol acyltransferase 2 ACAT-2 and incorporated along with triglycerides and apolipoprotein B into chylomicrons. Triglycerides are hydrolyzed by lipoprotein lipase and chylomicrons are transformed into chylomicron remnants that are taken up by the liver Figure 1.

Cholesterol metabolism and transport. NPC1L1 mediates the uptake of cholesterol and plant sterols into small intestinal epithelial cells.

Cholesterol is esterified and packaged into chylomicrons along with triglycerides. Ezetimibe inhibits NPC1L1 and decreases the intestinal cholesterol absorption. Cholesterol is synthesized in the liver and intestine. ABCA1 transporter mediates the efflux of cholesterol to a nascent HDL particle.

Cholesterol enters the hepatocytes via LDLr or the HDL receptor SR-B1. Bile acids are reabsorbed by ASBT in the ileum and activate FXR which increased the expression and secretion of FGF19 in humans 15 is rodents.

The de novo synthesis of cholesterol occurs in all cells in the body. However, the liver represents the main site for cholesterol synthesis and storage 8. Cholesterol synthesis starts with acetyl-CoA and involves multiple reactions.

The two rate-limiting steps in this complex process are mediated by 3-hydroxymethyl-glutaryl CoA reductase HMGCoAr and squalene monooxygenase. Cholesterol, the newly synthesized in the liver and the one derived from the intestinal absorption, is then packaged along with triglycerides and apolipoprotein B into the VLDL particles that are assembled by the microsomal transfer protein.

The VLDL loses its load of triglycerides while circulating in the tissues by lipoprotein lipase and transforms into LDL that represents the main vehicle of cholesterol transport to the peripheral tissues. The transport of cholesterol from the peripheral tissues back to liver is initiated by cholesterol efflux from cells via the ATP-binding cassette transporter ABCA1 to the nascent apolipoprotein A containing HDL particles.

Cholesterol could be transferred from HDL in the circulation to LDL by cholesterol-ester transfer protein CETP. HDL is taken up by hepatocytes via the scavenger receptor B1 SR-B1 8 Figure 1.

The expression of genes responsible for cholesterol transport and metabolism are tightly regulated by coordinated actions of transcription factors. For example, the decrease in the level of cellular cholesterol activates the ER membrane-bound transcription factor Sterol regulatory element-binding protein isoform 2 SREBP-2 that induces the expression of HMGCoAr and LDLr 8.

On the other hand, the increase in cellular cholesterol elevates the levels of the oxygenated cholesterol intermediates oxysterols that trigger Liver X receptors LXRs transcription factors to stimulate the pathways of cholesterol efflux and to promote cholesterol elimination from the liver 8.

The interest in understanding the relationship between cholesterol metabolism and the development of NAFLD and NASH was incited by observational studies linking liver damage with the risk for the development of cardiovascular disease CVD In fact, the increased prevalence of metabolic syndrome in patients with NAFLD was to such an extent that some authors suggested that NALFD represents the hepatic manifestation in a spectrum of metabolic disorders The metabolic syndrome refers to a cluster of metabolic disturbances including obesity, insulin resistance, hypertension, and atherogenic dyslipidemia that increase the risk for cardiovascular disease, stroke and diabetes mellitus Meta-analysis of observational retrospective and prospective studies demonstrated an increased risk for CVD of both fatal and non-fatal events of CVD in patients with NAFLD as compared to patients without NAFLD Such a link between NAFLD and CVD provided a compelling rationale to closely examine cholesterol metabolism in patients with NAFLD.

The features of dyslipidemia associated with NALFD include hypertriglyceridemia and a decrease in HDL cholesterol 2. Although there is no evidence for an increase in total LDL cholesterol, patients with NAFLD were shown to have elevated levels of highly atherogenic subpopulations of LDL such as the oxidized particles 2.

Furthermore, feeding high cholesterol atherogenic diets was able to induce lesions of early NAFLD as well as atherosclerosis in several animal models. It should be noted that animal species have remarkable differences in cholesterol metabolism and respond differently to cholesterol rich diet.

In this regard, it is well-established that rabbits have features of cholesterol metabolism that are closer to those in humans For example, the predominant plasma lipoproteins in both rabbits and humans is LDL whereas it the HDL in mice. This difference is due to the fact that the CETP is lacking in the plasma of mice More importantly, rabbits are sensitive to dietary cholesterol and develop severe hypercholesterolemia in response to high dietary cholesterol with prominent atherosclerosis This study generated evidence linking blood cholesterol with NAFLD and provided novel insights into the roles of free cholesterol in inducing liver damage.

In the mouse model, hypercholesterolemia and atherosclerosis can be produced only in genetically modified animals such as apoE and LDLr knockout mice In this regard, steatohepatitis was shown in apoE knockout mice in response to high fat high cholesterol feeding Combined transcriptomics and metabolomics analysis demonstrated that high dose of dietary cholesterol in apoE knockout mice triggered hepatic inflammation An interesting observation was made in wildtype mice but not in the transgenic mice models of hypercholesterolemia showing that high cholesterol in the diet was essential to elicit steatohepatitis and fibrosis after 30 weeks of feeding, whereas high fat diet alone failed to produce the same degree of liver injury This role of high dose of dietary cholesterol in the induction of liver damage in wildtype mice was also illustrated in other species.

Collectively, the evidence from preclinical animal models strongly indicate that a high dose of cholesterol is an independent risk factor for liver damage and the development of atherosclerosis.

A conclusion can be drawn from these studies linking NAFLD with atherosclerosis implicating the accumulation of cholesterol in the liver and arteries as a trigger for inflammation and subsequent manifestations of liver disease and CVD.

Puri et al. Collectively, the evidence from animal models and humans indicates that cholesterol is one of the toxic lipids that accumulates in the liver contributing to liver damage during the course of NAFLD and the progression to NASH.

Recent studies investigated the molecular mechanisms underlying the toxic effects of high cholesterol in the liver. The findings of Mari et al. Other studies suggested that the accumulated free cholesterol in damaged hepatocytes precipitates as crystals which in turn induce inflammatory response by interacting with NLRP3 inflammasomes of Kupffer cells Free cholesterol was shown also to directly accumulates in lysosomes of Kupffer cells triggering an inflammatory response Such inflammatory cascade was blocked by hyroxycholesterol that prevented the accumulation of cholesterol in Kupffer cells and reduced NASH.

The accumulation of cholesterol in hepatic stellate cells HSCs was also implicated in the progression to NASH and fibrosis For example, studies provided evidence showing that the accumulation of free cholesterol in HSCs resulted in an increase in the expression of TLR4 receptor and an increase in the sensitivity of HSCs to TGFb with subsequent fibrosis It is apparent therefore, that increased cellular levels of cholesterol in different cell types in the liver may be responsible for liver damage and the progression from simple steatosis to NASH.

The accumulation of free cholesterol in NAFLD may occur due to an upregulation in the input pathways or a decrease in the elimination of cholesterol. There is evidence to suggest that changes in microRNAs miRs might be responsible for the observed increase in HMGCoAr.

Several studies demonstrated the roles of several miRs in the development of liver diseases including NAFLD. The roles of these miRs including miR, miR, and miRa are discussed in details in other excellent review articles 31 , Studies have also demonstrated the regulation of several genes involved in cholesterol metabolism such as HMGCoAr by miRs and these findings are nicely summarized in other review articles 33 , The roles of miRa was also suggested by a supporting evidence showing a negative correlation between miRa and HMGCoAr expression after 3 weeks feeding of methionine-choline deficient diet MCD to mice The decrease in miRa was concomitant with a decrease in hepatic Dicer1 enzyme that is essential for the maturation of microRNAs.

In fact, liver-specific knockout of Dicer1 enzyme resulted in an increase in HMGCoAr associated with accumulation of free cholesterol in the liver Since SREBP2 induces the expression HMGCoAr, the observed increase in active SERBP2 represents an additional molecular pathway that might be responsible for the increases in hepatic levels of free cholesterol.

Mari et al. It should be noted that the accumulation of free cholesterol in hepatocytes is expected to inhibit the activation of SREBP2 Indeed, a previous study showed that the injection of cytokines in C57BL mice resulted in an increase in hepatic SREBP2 and HMGCoAr expression Similar findings were obtained in response to incubation of human hepatic HepG2 cells with cytokines.

Although loading of HepG2 cells with cholesterol inhibited the SREBP2 pathways as expected, such a negative feedback inhibition was overridden by inflammatory stress caused by the cytokines It is also reported that miR stabilizes the inactive form of SREBP2 Interestingly, miR was shown to be significantly decreased in patients with NASH, thus providing a potential explanation for the increase in SREBP2 It is possible also that hyperinsulinemia resulted from increased insulin resistance may also cause an increase in the active form of SREBP2 Collectively, the inflammatory stress, the decrease in miR and associated hyperinsulinemia in NASH presents a reasonable explanation for the constant activation of SREBP2 bypassing the canonical negative feedback inhibitory effect of high levels of cellular cholesterol Beside the increase in cholesterol synthesis, changes in the pathways involved in the elimination of cholesterol were also noted in patients with NASH.

Among these observations is the decrease in the expression of CYP7A1 implicating reduced bile acid synthesis from cholesterol With respect to dietary cholesterol and liver disease in humans, an epidemiological study suggested that dietary cholesterol is an independent risk factor for liver cirrhosis and hepatic cancer These studies provide support to the observations made in animal models demonstrating the role of cholesterol in the induction of liver damage 43 , One study by Simonen et al.

The authors found that the content of liver fat was positively correlated with markers of cholesterol synthesis and inversely correlated with markers of cholesterol absorption It is possible that there is an interrelationship between these two processes so that the decrease in cholesterol absorption may represent a homeostatic response to an increase in cholesterol synthesis It will be important to investigate a possible difference in the efficiency of cholesterol absorption in patients with NASH as compared to those with NAFLD.

With respect to the expression of intestinal NPC1L1, previous studies showed an increase in the expression of this intestinal in patients with diabetes mellitus It is of central importance to investigate the expression of NPC1L1 in patients with NAFLD and NASH to a make a conclusion regarding potential changes in cholesterol absorption.

Also, the studies mentioned above assessed the efficiency of cholesterol absorption indirectly by measuring serum plant sterols as surrogate markers. According to current guidelines, decreasing the levels of plasma cholesterol to stringent low levels is highly recommended in patients with high risk for CVD 47 , Therefore, it is of central importance to address treatment options available to lower plasma cholesterol in this patient population.

Table 1 summarizes the results of selected studies related to cholesterol-based therapy for NAFLD. Statins, the inhibitors of HMGCoAr, are the widely used drugs to lower plasma cholesterol It is well-established that statins reduce LDL cholesterol and significantly decrease the risk for CVD.

Thus, it is logical to use statins in NAFLD patients who are at risk for CVD However, recent studies in a cohort of ~1, European patients provided strong evidence demonstrating the beneficial effects of statins in the protection against steatosis, steatohepatitis, and fibrosis as assessed by liver biopsies The effects of statins on several aspects of liver injury was shown in animal models Statins were shown to decrease experimentally induced fibrosis in rats by inhibiting the activation of hepatic stellate cells Recent study also showed that simvastatin reduced liver inflammation and fibrosis in ApoE knockout mice fed with western-type of diet These effects were attributed to the inhibition of RhoA and Ras signaling It is possible therefore, that the amelioration of liver injury by statins is due to other effects beside the inhibition of cholesterol synthesis Statins may also affect cholesterol metabolism in other organs and indirectly influence liver function.

For example, it was shown that statin treatment in humans increased the expression of intestinal SREBP2 In this regard, our studies demonstrated that the intestine-specific overexpression of SREBP2 caused hepatic steatosis and profound diet-induced liver injury in mice It is possible therefore, that statins may negatively affect liver function by increasing intestinal SREBP2 expression.

Blocking the absorption of bile acids eliminates the negative feedback inhibition on their hepatic synthesis and promotes cholesterol degradation Recent studies provided a compelling evidence showing that the lack of ASBT in knockout mice protected against diet-induced liver injury and steatosis Further, these studies showed that the pharmacological inhibition of ASBT significantly decreased hepatic triglycerides and total cholesterol and improved NAFLD activity score Additional studies using the ASBT inhibitor volixibat in LDLr leiden knockout mice supported that conclusion and demonstrated a significant decrease in diet-induced Non-alcoholic fatty liver disease activity score by the inhibition of ASBT In humans however, a phase 2 clinical trial to assess the effects of 48 weeks treatment with the ASBT inhibitor, volixibat, was terminated after mid-term assessment due to lack of improvement in NASH score as judged by MRI-PDFF imaging It should be noted that the histological evaluations including the scores for ballooning and inflammation in this clinical trial were lacking.

Studies showed that the inhibitor of cholesterol absorption ezetimibe reduces plasma cholesterol and decreases the risk of CVD when used alone or in combination with statins 67 , Takeshita et al. However, the clinical trial by Loomba et al.

It is noteworthy to mention that the inter-individual variations in the efficiency in cholesterol absorption may influence the results of these studies. An increase in cholesterol synthesis and a decrease in the pathways responsible for the elimination of cholesterol lead to accumulation of free cholesterol in the liver.

The toxicity of high cellular levels of cholesterol in hepatocytes is one of the major factors causing inflammation and fibrosis leading to liver damage. One challenging area is the complex nature of the processes involved in cholesterol homeostasis.

Such variations evoke the need for precision medicine approaches and individualized treatment. It is possible that individuals with naturally occurring low efficiency of cholesterol absorption may not benefit from the use of cholesterol absorption blocker ezetimibe. Your liver does much more than you probably give it credit for.

Yes, the liver and cholesterol go hand in hand, but what does that mean for you in terms of cholesterol management? It does this by converting the cholesterol to bile salts and transferring the compounds into the bile, where they are ultimately expelled from the body.

In addition, your liver synthesizes most of the necessary lipoproteins needed to transport cholesterol and lipids throughout your body.

These processes allow you to manage your cholesterol and maintain a healthy heart…assuming that your liver is doing its job. As you can imagine, this is going to lead to a messy disaster before too long.

For more information on your liver and cholesterol, speak to a professional and get the help you need to live a long and prosperous life, free from the dangers of high cholesterol and heart disease. I read a lot of interesting content here.

In fact, people with genetic mutations that cause them to have extremely low levels of blood cholesterol—even in the single digits—show no significant side effects.

He notes that babies potentially need the most cholesterol as they grow and develop. Yet babies are completely healthy having half as much cholesterol as the average American adult. When you have lots of cholesterol in your body, it builds up wherever it can.

Over time, it accumulates in the artery walls, leading to heart attack or stroke. You can do a few key things to reduce your cholesterol and prevent disease, including:. Skip to cookie consent Skip to main content Skip to alerts Skip to pause carousel.

About Us Newsroom How Is Cholesterol Produced? More alert details. How Is Cholesterol Produced? Contributor: Romit Bhattacharya, MD. Apr 7, share on facebook. How does the liver make cholesterol?

Excess LDL can deposit fat and cholesterol in your artery walls. Very-low-density lipoproteins VLDL are similar to LDL, but mainly carry triglycerides a type of fat.

It brings the excess back to your liver to ultimately get flushed out of your body. Your blood has 2 main types of these cholesterol molecules: Low-density lipoproteins LDL : LDL cholesterol carries molecules from one part of your body to another.

When your body produces cholesterol, the amount of HDL compared to LDL matters. A healthy diet and lifestyle decrease LDL cholesterol, in addition to decreasing your total cholesterol. As a result, the ratio of HDL to LDL improves. When you eat sugar, your body releases a hormone called insulin.

Insulin controls many processes in the body, but importantly, it signals to your liver to make more cholesterol. In fact, people with genetic mutations that cause them to have extremely low levels of blood cholesterol—even in the single digits—show no significant side effects.

He notes that babies potentially need the most cholesterol as they grow and develop. Yet babies are completely healthy having half as much cholesterol as the average American adult. When you have lots of cholesterol in your body, it builds up wherever it can. Over time, it accumulates in the artery walls, leading to heart attack or stroke.

You can do a few key things to reduce your cholesterol and prevent disease, including:. Skip to cookie consent Skip to main content Skip to alerts Skip to pause carousel. About Us Newsroom How Is Cholesterol Produced?

More alert details. How Is Cholesterol Produced? Contributor: Romit Bhattacharya, MD. Apr 7, share on facebook. How does the liver make cholesterol? Excess LDL can deposit fat and cholesterol in your artery walls. Very-low-density lipoproteins VLDL are similar to LDL, but mainly carry triglycerides a type of fat.

It brings the excess back to your liver to ultimately get flushed out of your body. Your blood has 2 main types of these cholesterol molecules: Low-density lipoproteins LDL : LDL cholesterol carries molecules from one part of your body to another.

High-density lipoproteins HDL : HDL cholesterol soaks up extra cholesterol and fat throughout your body like a sponge. No cholesterol level in the blood has ever shown to be too low for humans. Romit Bhattacharya, MD Cardiologist Mass General Brigham. How much cholesterol is produced by the body?

However, there are some limitations to this study. First, the cross-sectional nature of the data may affect the relationship between lipid profile markers and liver enzymes. Moreover, the sample size was relatively small and the study was conducted in a divisional region of Bangladesh, thus our findings may not be nationally representative.

However, our findings may be worth reference to future studies. A high prevalence of dyslipidemia and liver enzyme abnormalities was observed among the Bangladeshi adults; higher in diabetic and hypertensive subjects than in the healthy subjects.

A higher frequency of elevated liver enzymes was observed in subjects with dyslipidemia. Of the four liver enzymes, only serum GGT showed the strongest relationship with the lipid profile markers. The elevated level of lipids and GGT in the blood may be a better indicator to monitor the progression and severity of lipid-induced hepatic dysfunctions and associated complications.

This study finding indicates that dyslipidemic individuals may have a higher chance of developing liver disease than non-dyslipidemic individuals.

A large-scale prospective study is needed to understand the underlying mechanisms of lipid-induced hepatic dysfunction in the Bangladeshi population. Ciffone, N. Managing dyslipidemia for CVD prevention: A review of recent clinical practice guidelines.

Nurse Pract. PubMed Google Scholar. Pirillo, A. Global epidemiology of dyslipidaemias. Cardiol 18 , — CAS PubMed Google Scholar. Farzadfar, F. National, regional, and global trends in serum total cholesterol since Systematic analysis of health examination surveys and epidemiological studies with country-years and 3·0 million participants.

Lancet , — Htet, A. et al. Lipid profiles and determinants of total cholesterol and hypercholesterolaemia among 25—74 year-old urban and rural citizens of the Yangon Region, Myanmar: A cross-sectional study.

BMJ Open 7 , 1—8 Google Scholar. Joshi, S. Prevalence of dyslipidemia in urban and rural India: The ICMR-INDIAB study. PLoS ONE 9 , e ADS PubMed PubMed Central Google Scholar.

Zhang, F. The prevalence, awareness, treatment, and control of dyslipidemia in northeast China: A population-based cross-sectional survey. Lipids Health Dis. PubMed PubMed Central Google Scholar. Stamler, J. Established major coronary risk factors: Historical overview.

Marmot M. Elliot P. Coronary Heart Disease Epidemiology: From Aetiology to Public Health 2 , 18—31 World Health Organization Noncommunicable Diseases Country Profiles. WHO Library Cataloguing-in-Publication Data, Geneva, Switzerland 7 World Health Organization.

Cardiovascular diseases CVDs fact sheet. World Health Organization Badimon, L. LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: Inflammatory resolution versus thrombotic chaos. ADS CAS PubMed Google Scholar.

Najeeb, Q. Association of lipid profile and liver enzymes among non-alcoholic fatty liver disease patients attending a tertiary care hospital in northern indian. Ahmed, M. Non-alcoholic fatty liver disease in World J. Ge, X. Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, — A population-based observational study.

BMJ Open 10 , e Ray, K. NAFLD-the next global epidemic. Alam, S. Prevalence and risk factors of non-alcoholic fatty liver disease in Bangladesh.

JGH Open 2 , 39—46 Hanigan, M. Immunohistochemical detection of y-glutamyl transpeptidase in normal human tissue. Whitfield, J. Gamma glutamyl transferase. Giannini, E. Liver enzyme alteration: A guide for clinicians. CMAJ , — Islam, S. Prevalence of elevated liver enzymes and its association with type 2 diabetes: A cross-sectional study in Bangladeshi adults.

Diabetes Metab 3 , e CAS PubMed PubMed Central Google Scholar. Kim, D. Serum γ-glutamyltransferase within its normal concentration range is related to the presence of diabetes and cardiovascular risk factors. Lee, D. Association between serum gamma-glutamyltransferase and C-reactive protein.

Atherosclerosis , — Sanyal, D. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes.

Indian J. Metab 19 , — Nelson, R. Hyperlipidemia as a risk factor for cardiovascular disease. Primary Care: Clin. Office Pract. Deb, S. A Population-Based Cross-Sectional Study of the Association. Fatema, K. Prevalence of risk factors for cardiovascular diseases in Bangladesh: A systematic review and meta-analysis.

PLoS ONE 11 , 1—14 Islam, N. Prevalence of dyslipidemia and associated factors among the sub-urban Bangladeshi population. Heart J. Mostafa Zaman, M. Plasma lipids in a rural population of Bangladesh. Groups Epidemiol. Cardiac Rehab. Exercise Physiol. CAS Google Scholar.

Ali, N. Hypertension prevalence and influence of basal metabolic rate on blood pressure among adult students in Bangladesh. BMC Public Health 18 , 58 Prevalence of hyperuricemia and the relationship between serum uric acid and obesity: A study on Bangladeshi adults. PLoS ONE 13 , e The relationship between serum uric acid and lipid profile in Bangladeshi adults.

BMC Cardiovasc. Relationship between serum uric acid and hypertension: A cross-sectional study in Bangladeshi adults. Association between serum uric acid and metabolic syndrome: A cross-sectional study in Bangladeshi adults.

ADS CAS PubMed PubMed Central Google Scholar. Assessment of the relationship of serum liver enzymes activity with general and abdominal obesity in an urban Bangladeshi population. Haque, T. Assessment of the relationship between serum uric acid and glucose levels in healthy, prediabetic and diabetic individuals.

Metab Syndr. Rahman, S. Association between serum liver enzymes and hypertension: A cross-sectional study in Bangladeshi adults.

Molla, N. Assessment of the relationship between serum uric acid levels and liver enzymes activity in Bangladeshi adults. Article PubMed PubMed Central Google Scholar. Mou, A. Prevalence of preeclampsia and the associated risk factors among pregnant women in Bangladesh.

Expert Panel on Detection, E. and T. Executive Summary of the Third Report NCEP -Adult Treatment Panel III. Schumann, G. New IFCC reference procedures for the determination of catalytic activity concentrations of five enzymes in serum: Preliminary upper reference limits obtained inhospitalized subjects.

Acta , 69—79 Tietz, N. Reference intervals for alkaline phosphatase activity determined by the IFCC and AACC reference methods. Marathe, P. American diabetes association standards of medical care in diabetes Diabetes 9 , — Ahsan, S.

Detection of ischaemic heart disease with risk factors in different categories of employees of University Grants Commission. Bhowmik, B. Serum lipid profile and its association with diabetes and prediabetes in a rural bangladeshi population. Public Health 15 , PubMed Central Google Scholar.

Choudhury, K. Serum lipid profile and its association with hypertension in Bangladesh. Health Risk Manag. Alshamiri, M. Expert opinion on the applicability of dyslipidemia guidelines in Asia and the middle east.

Monwarul Islam, A. Coronary artery disease in Bangladesh: A review. Indian Heart J. Kumar Das, S. Serum lipid profile among urban and rural Bangladeshi population. Weight Loss Ther. Atiba, A. Liver enzymes and lipid profile among type 2 diabetic patients in Osogbo, By.

Greener J. Kim, H. Association between serum liver enzymes and metabolic syndrome in Korean adults. Hanley, A. Elevations in markers of liver injury and risk of type 2 diabetes. Diabetes 53 , — de Souza, L. Prevalence of dyslipidemia and risk factors in Campos dos Goytacazes, in the Brazilian State of Rio de Janeiro.

Lieber, C. Alcoholic fatty liver: Its pathogenesis and mechanism of progression to inflammation and fibrosis. in Alcohol vol. Arauz, J. Redox state and methods to evaluate oxidative stress in liver damage: From bench to bedside. Review is serum gamma glutamyltransferase a marker of oxidative stress?.

Free Radical Res. Download references. Department of Biochemistry and Molecular Biology, Shahjalal University of Science and Technology, Sylhet, , Bangladesh. You can also search for this author in PubMed Google Scholar.

contributed to the conception and design of the study, data interpretation and drafting of the manuscript. collected the samples, conducted the experiments and drafted some parts of the manuscript.

and R. assisted in lab experiments and data analysis. and A. helped in sample and data collection. All authors contributed to manuscript revision, read and approved the submitted version. Correspondence to Nurshad Ali. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.

If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

Reprints and permissions. Kathak, R. The association between elevated lipid profile and liver enzymes: a study on Bangladeshi adults. Sci Rep 12 , Download citation. Received : 31 July Accepted : 14 January Published : 02 February Anyone you share the following link with will be able to read this content:.

Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative. By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma. Skip to main content Thank you for visiting nature. nature scientific reports articles article. Download PDF.

Subjects Biomarkers Diagnostic markers. Abstract Dyslipidemia, a major contributor to cardiovascular diseases, is rapidly increasing in Asian countries including Bangladesh.

Introduction Dyslipidemia is a major contributor to cardiovascular diseases CVDs and considered a global public health challenge 1 , 2. Methods Study design and participant selection A cross-sectional population-based study was conducted between December and February at the Department of Biochemistry and Molecular Biology, SUST, Bangladesh.